Park Avenue Securities LLC purchased a new stake in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 10,085 shares of the company’s stock, valued at approximately $656,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Western Wealth Management LLC purchased a new stake in SPDR S&P Pharmaceuticals ETF during the 1st quarter worth $34,000. Fifth Third Bancorp purchased a new position in SPDR S&P Pharmaceuticals ETF in the 1st quarter valued at about $39,000. TD Waterhouse Canada Inc. purchased a new position in SPDR S&P Pharmaceuticals ETF in the 2nd quarter valued at about $200,000. Corient Private Wealth LP purchased a new position in SPDR S&P Pharmaceuticals ETF in the 2nd quarter valued at about $225,000. Finally, Kaizen Financial Strategies acquired a new stake in shares of SPDR S&P Pharmaceuticals ETF during the third quarter valued at about $228,000.
SPDR S&P Pharmaceuticals ETF Price Performance
Shares of SPDR S&P Pharmaceuticals ETF stock opened at $65.36 on Thursday. SPDR S&P Pharmaceuticals ETF has a 1-year low of $47.60 and a 1-year high of $74.35. The company has a market capitalization of $454.25 million, a PE ratio of 14.28 and a beta of 0.62. The business has a 50-day moving average of $66.10 and a 200-day moving average of $61.84.
SPDR S&P Pharmaceuticals ETF Profile
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
